Thalys Medical Technology Group Corporation (SHA:603716)
China · Delayed Price · Currency is CNY 16.74
-0.16 (-0.95%)
Sep 22, 2026, 9:35 AM CST
SHA:603716 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,749 | 4,238 | 1,350 | 2,126 | 2,115 | 2,800 | |
Market Cap Growth | -30.29% | 213.84% | -36.50% | 0.51% | -24.45% | -14.23% |
Enterprise Value | 3,840 | 4,643 | 2,305 | 3,163 | 3,337 | 3,959 |
Last Close Price | 16.90 | 20.55 | 7.22 | 11.09 | 11.04 | 14.39 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 35.82 | 35.82 | 35.82 | 35.82 | 35.82 |
PS Ratio | 4.48 | 3.94 | 0.75 | 1.06 | 0.92 | 1.08 |
PB Ratio | 3.65 | 4.68 | 1.40 | 1.62 | 1.41 | 1.61 |
P/TBV Ratio | 3.58 | 4.71 | 1.57 | 2.00 | 1.72 | 2.04 |
P/FCF Ratio | 988.98 | - | 17.68 | 25.00 | - | - |
P/OCF Ratio | 565.11 | - | 13.56 | 16.89 | 75.23 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.59 | 4.31 | 1.27 | 1.58 | 1.45 | 1.52 |
EV/EBITDA Ratio | - | - | 52.61 | 94.19 | 73.79 | 23.73 |
EV/EBIT Ratio | - | - | 300.85 | - | - | 41.75 |
EV/FCF Ratio | 1013.01 | - | 30.18 | 37.19 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.25 | 0.50 | 0.96 | 0.80 | 0.94 | 0.92 |
Debt / EBITDA Ratio | - | - | 15.32 | 18.82 | 20.41 | 8.37 |
Debt / FCF Ratio | 66.88 | - | 12.11 | 12.34 | - | - |
Net Debt / Equity Ratio | 0.15 | 0.36 | 0.74 | 0.59 | 0.68 | 0.64 |
Net Debt / EBITDA Ratio | -2.42 | -8.51 | 16.33 | 22.97 | 22.34 | 6.68 |
Net Debt / FCF Ratio | 41.50 | -7.41 | 9.37 | 9.07 | -38.10 | -5.75 |
Asset Turnover | 0.44 | 0.47 | 0.59 | 0.55 | 0.56 | 0.63 |
Inventory Turnover | 3.01 | 3.08 | 4.44 | 4.24 | 4.21 | 4.75 |
Quick Ratio | 1.41 | 1.10 | 1.23 | 1.42 | 1.32 | 1.53 |
Current Ratio | 1.90 | 1.42 | 1.52 | 1.72 | 1.61 | 1.87 |
Return on Equity (ROE) | -21.49% | -21.58% | -16.99% | -11.15% | -11.74% | -2.17% |
Return on Assets (ROA) | -2.92% | -1.76% | 0.15% | -0.32% | -0.24% | 1.44% |
Return on Invested Capital (ROIC) | -7.48% | -4.48% | 0.41% | -0.82% | -0.58% | 3.51% |
Return on Capital Employed (ROCE) | -8.40% | -7.00% | 0.50% | -1.00% | -0.70% | 3.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -5.31% | -4.89% | -15.50% | -7.46% | -7.27% | -1.77% |
FCF Yield | 0.10% | -1.03% | 5.66% | 4.00% | -1.25% | -6.92% |
Buyback Yield / Dilution | -24.46% | -3.61% | 0.73% | 0.62% | 1.73% | 0.23% |
Total Shareholder Return | -24.46% | -3.61% | 0.73% | 0.62% | 1.73% | 0.23% |